This KIR2DL3 antibody is conjugated to PerCP-Cy5.5
Application
Flow Cytometry (FACS)
Purification
The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.
CD158B2 antibody, CD158b antibody, GL183 antibody, KIR-023GB antibody, KIR-K7b antibody, KIR-K7c antibody, KIRCL23 antibody, NKAT antibody, NKAT2 antibody, NKAT2A antibody, NKAT2B antibody, p58 antibody, killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 antibody, KIR2DL3 antibody
Background
CD158b is expressed on natural killer cells and a subset of T cells. It is a member of the immunoglobulin superfamily containing two immunoglobulin C2-type domains. Both variants and alternative isoforms of CD158b have been reported. The interaction of CD158b with specific HLA-C antigens on a target cell (HLA-Cw1, HLA-Cw3, HLA-Cw7 alleles, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK cell and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.